In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Picking up the Pacing in Obesity: Medtronic acquires Transneuronix

Executive Summary

Medtronic soon will be able to offer a less invasive and safer surgical alternative to gastric bypass surgery, now that it has acquired Transneuronix for $260 million. Transneuronix has developed a gastric pacing device known as Transcend, which stimulates the stomach, and it appears to affect multiple mechanisms in obesity. The device has been approved in Europe, and has been implanted in more than 700 patients worldwide. In the US, Transneuronix has completed enrollment for its pivotal clinical trial.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts